Vis enkel innførsel

dc.contributor.authorAasebø, Elise
dc.contributor.authorBrenner, Annette
dc.contributor.authorHernandez-Valladares, Maria
dc.contributor.authorBirkeland, Even
dc.contributor.authorBerven, Frode Steingrimsen
dc.contributor.authorSelheim, Frode
dc.contributor.authorBruserud, Øystein
dc.date.accessioned2021-11-02T08:11:04Z
dc.date.available2021-11-02T08:11:04Z
dc.date.created2021-05-28T14:33:02Z
dc.date.issued2021
dc.identifier.issn1422-0067
dc.identifier.urihttps://hdl.handle.net/11250/2827137
dc.description.abstractMesenchymal stem cells (MSCs) can differentiate into osteoblasts, and therapeutic targeting of these cells is considered both for malignant and non-malignant diseases. We analyzed global proteomic profiles for osteoblasts derived from ten and MSCs from six healthy individuals, and we quantified 5465 proteins for the osteoblasts and 5420 proteins for the MSCs. There was a large overlap in the profiles for the two cell types; 156 proteins were quantified only in osteoblasts and 111 proteins only for the MSCs. The osteoblast-specific proteins included several extracellular matrix proteins and a network including 27 proteins that influence intracellular signaling (Wnt/Notch/Bone morphogenic protein pathways) and bone mineralization. The osteoblasts and MSCs showed only minor age- and sex-dependent proteomic differences. Finally, the osteoblast and MSC proteomic profiles were altered by ex vivo culture in serum-free media. We conclude that although the proteomic profiles of osteoblasts and MSCs show many similarities, we identified several osteoblast-specific extracellular matrix proteins and an osteoblast-specific intracellular signaling network. Therapeutic targeting of these proteins will possibly have minor effects on MSCs. Furthermore, the use of ex vivo cultured osteoblasts/MSCs in clinical medicine will require careful standardization of the ex vivo handling of the cells.en_US
dc.language.isoengen_US
dc.publisherMDPIen_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleProteomic Comparison of Bone Marrow Derived Osteoblasts and Mesenchymal Stem Cellsen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionpublishedVersionen_US
dc.rights.holderCopyright 2021 by the authors.en_US
dc.source.articlenumber5665en_US
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.doi10.3390/ijms22115665
dc.identifier.cristin1912574
dc.source.journalInternational Journal of Molecular Sciencesen_US
dc.relation.projectKreftforeningen: 100933en_US
dc.relation.projectNorges forskningsråd: 295910en_US
dc.identifier.citationInternational Journal of Molecular Sciences. 2021, 22 (11), 5665.en_US
dc.source.volume22en_US
dc.source.issue11en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal